Are you Dr. Gault?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 30 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
342 Harbor St
Branford, CT 06405Phone+1 203-481-4248Fax+1 203-483-7727
Summary
- Dr. Laura Gault, MD is a psychiatrist in Branford, Connecticut. She is currently licensed to practice medicine in Connecticut.
Education & Training
Yale-New Haven Medical CenterFellowship, Child and Adolescent Psychiatry, 2003 - 2006- Yale-New Haven Medical CenterResidency, Pediatrics, 1999 - 2002
- Yale-New Haven Medical CenterInternship, Transitional Year, 2000 - 2001
Case Western Reserve University School of MedicineClass of 1999
Certifications & Licensure
CT State Medical License 2002 - 2021
Clinical Trials
- A Safety and Tolerability Study of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD) Start of enrollment: 2007 Feb 01
- A Safety and Efficacy Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) Start of enrollment: 2007 Sep 01
- A Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) Start of enrollment: 2007 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- 100 citationsTau: From research to clinical development.David M. Holtzman, Maria C. Carrillo, James Hendrix, Lisa J. Bain, Ana M. Catafau
Alzheimer's & Dementia. 2016-10-01 - 27 citationsEfficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Pl...Hana Florian, Andreas Meier, Serge Gauthier, Stanley Lipschitz, Yunzhi Lin
Journal of Alzheimer's Disease. 2016-01-01 - 41 citationsEfficacy and safety of the novel α4β2 neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double...George Apostol, Walid M. Abi-Saab, Christopher J. Kratochvil, Lenard A. Adler, Weining Z. Robieson
Psychopharmacology. 2012-02-01
Press Mentions
A New Fast-Acting Pill for Postpartum Depression May Soon Be AvailableFebruary 17th, 2023- The Top Doctor at a $2.7 Billion Pharma Company Developing a New Depression Drug Says We May Be 'On the Cusp' of a New Wave of Mental-Health TreatmentsFebruary 13th, 2023
- First Pill to Treat Postpartum Depression Moves to FDA for ReviewFebruary 8th, 2023
- Join now to see all
